Literature DB >> 11400159

Adenovirus-mediated BMP2 expression in human bone marrow stromal cells.

E A Olmsted1, J S Blum, D Rill, P Yotnda, Z Gugala, R W Lindsey, A R Davis.   

Abstract

Recombinant adenoviral vectors have been shown to be potential new tools for a variety of musculoskeletal defects. Much emphasis in the field of orthopedic research has been placed on developing systems for the production of bone. This study aims to determine the necessary conditions for sustained production of high levels of active bone morphogenetic protein 2 (BMP2) using a recombinant adenovirus type 5 (Ad5BMP2) capable of eliciting BMP2 synthesis upon infection and to evaluate the consequences for osteoprogenitor cells. The results indicate that high levels (144 ng/ml) of BMP2 can be produced in non-osteoprogenitor cells (A549 cell line) by this method and the resultant protein appears to be three times more biologically active than the recombinant protein. Surprisingly, similar levels of BMP2 expression could not be achieved after transduction with Ad5BMP2 of either human bone marrow stromal cells or the mouse bone marrow stromal cell line W20-17. However, human bone marrow stromal cells cultured with 1 microM dexamethasone for four days, or further stimulated to become osteoblast-like cells with 50 microg/ml ascorbic acid, produced high levels of BMP2 upon Ad5BMP2 infection as compared to the undifferentiated cells. The increased production of BMP2 in adenovirus transduced cells following exposure to 1 microM dexamethasone was reduced if the cells were not given 50 microg/ml ascorbic acid. When bone marrow stromal cells were allowed to become confluent in culture prior to differentiation, BMP2 production in response to Ad5BMP2 infection was lost entirely. Furthermore, the increase in BMP2 synthesis seen during differentiation was greatly decreased when Ad5BMP2 was administered prior to dexamethasone treatment. In short, the efficiency of adenovirus mediated expression of BMP2 in bone marrow stromal cells appears to be dependent on the differentiation state of these cells. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11400159     DOI: 10.1002/jcb.1106

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  14 in total

1.  [Experimental pilot study on surface activation of implants with liposomal vectors].

Authors:  M Thorwarth; K A Schlegel; J Wiltfang; S Rupprecht; J H Park
Journal:  Mund Kiefer Gesichtschir       Date:  2004-03-27

Review 2.  Mesenchymal stem cells: lineage, plasticity, and skeletal therapeutic potential.

Authors:  Richard O C Oreffo; Cyrus Cooper; Christopher Mason; Mark Clements
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

3.  Hypoxic adipocytes pattern early heterotopic bone formation.

Authors:  Elizabeth Olmsted-Davis; Francis H Gannon; Mustafa Ozen; Michael M Ittmann; Zbigniew Gugala; John A Hipp; Kevin M Moran; Christine M Fouletier-Dilling; Shannon Schumara-Martin; Ronald W Lindsey; Michael H Heggeness; Malcolm K Brenner; Alan R Davis
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

4.  Hydrogel microsphere encapsulation of a cell-based gene therapy system increases cell survival of injected cells, transgene expression, and bone volume in a model of heterotopic ossification.

Authors:  Ronke M Olabisi; Zawaunyka W Lazard; Christy L Franco; Mary A Hall; Sun Kuk Kwon; Eva M Sevick-Muraca; John A Hipp; Alan R Davis; Elizabeth A Olmsted-Davis; Jennifer L West
Journal:  Tissue Eng Part A       Date:  2010-09-01       Impact factor: 3.845

5.  Characterization of chemical, radiochemical and optical properties of a dual-labeled MMP-9 targeting peptide.

Authors:  Ali Azhdarinia; Nathaniel Wilganowski; Holly Robinson; Pradip Ghosh; Sunkuk Kwon; Zawaunyka W Lazard; Alan R Davis; Elizabeth Olmsted-Davis; Eva M Sevick-Muraca
Journal:  Bioorg Med Chem       Date:  2011-05-06       Impact factor: 3.641

6.  Development of a Cell-Based Gene Therapy Approach to Selectively Turn Off Bone Formation.

Authors:  Pedro Alvarez-Urena; Banghe Zhu; Gabrielle Henslee; Corinne Sonnet; Eleanor Davis; Eva Sevick-Muraca; Alan Davis; Elizabeth Olmsted-Davis
Journal:  J Cell Biochem       Date:  2017-07-31       Impact factor: 4.429

7.  Cell-based gene therapy for repair of critical size defects in the rat fibula.

Authors:  Zawaunyka W Lazard; Michael H Heggeness; John A Hipp; Corinne Sonnet; Angie S Fuentes; Rita P Nistal; Alan R Davis; Ronke M Olabisi; Jennifer L West; Elizabeth A Olmsted-Davis
Journal:  J Cell Biochem       Date:  2011-06       Impact factor: 4.429

8.  Matrix GLA protein function in human trabecular meshwork cells: inhibition of BMP2-induced calcification process.

Authors:  Wei Xue; Reidar Wallin; Elizabeth A Olmsted-Davis; Teresa Borrás
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-03       Impact factor: 4.799

9.  Development of a model of elevated intraocular pressure in rats by gene transfer of bone morphogenetic protein 2.

Authors:  Lakisha K Buie; Md Zahidul Karim; Matthew H Smith; Teresa Borrás
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-08-13       Impact factor: 4.799

10.  An injectable method for noninvasive spine fusion.

Authors:  Ronke M Olabisi; ZaWaunyka Lazard; Michael H Heggeness; Kevin M Moran; John A Hipp; Ashvin K Dewan; Alan R Davis; Jennifer L West; Elizabeth A Olmsted-Davis
Journal:  Spine J       Date:  2011-02-02       Impact factor: 4.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.